Email: cspc@cspc.cn
News
News Center
Mar. 21
2024
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL
Mar. 19
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL
Mar. 15
CSPC Innovation Included in FTSE Global Equity Index Series
Stroke: Butylphthalide Improves Post-Stroke Cognitive Impairment in Non-Human Primate
CSPC Acarbose Receives EU GMP Certificate
Two Studies of CSPC Presented at the International Stroke Conference
Contact Us
phones:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
